THE PRIMARY ENDPOINT OF BIO-RISE CHINA WAS PRESENTED AT TCT 2021 LATE BREAKING TRIALS
This first-in-human study assessed the safety and efficacy of a Biolimus A9™ coated balloon and showed excellent results in small vessels with 0.16 mm late loss at 9 months.